Skip to main content
PMC home page
Springer logoLink to Springer
. 2021 Oct 13;22(6):905. doi: 10.1007/s40257-021-00638-z

Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Eric L Simpson 1, Jonathan I Silverberg 2, Audrey Nosbaum 3, Kevin L Winthrop 1, Emma Guttman-Yassky 4, Karin M Hoffmeister 5,6, Alexander Egeberg 7, Hernan Valdez 8, Min Zhang 9, Saleem A Farooqui 10, William Romero 11, Andrew J Thorpe 12, Ricardo Rojo 13, Susan Johnson 12,✉
PMCID: PMC9172826  PMID: 34642878

Correction to: American Journal of Clinical Dermatology (2021) 22:693–707 10.1007/s40257-021-00618-3

The article was originally published electronically on SpringerLink on 18 August 2021. After publication in volume 22, issue 5, pages 693–707, the authors highlighted that, in Supplemental Table 1, the overall patient numbers for the JADE MONO-2 and JADE COMPARE studies were incorrect. These errors have been rectified and a new corrected version of Supplementary file 1 has been uploaded with the manuscript on SpringerLink.

The original article has been corrected.

Articles from American Journal of Clinical Dermatology are provided here courtesy of Springer

RESOURCES